Edesa Biotech (EDSA) Free Cash Flow (2013 - 2025)

Edesa Biotech has reported Free Cash Flow for 13 years, with the latest figure at -$2.1 million in Q4 2025.

• Quarterly Free Cash Flow fell 38.41% year-over-year to -$2.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$7.9 million (down 57.32% YoY) and the FY2025 annual result came in at -$7.3 million, down 48.98% from the prior year.
• Free Cash Flow declined to -$2.1 million in Q4 2025 per EDSA's latest filing, from -$1.7 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$353857.0 in Q3 2021 and troughed at -$7.2 million in Q1 2021.
• A 5-year average of -$2.2 million and a median of -$1.7 million in 2025 frame the typical range for Free Cash Flow.
• The widest YoY moves for Free Cash Flow: up 94.18% in 2022, down 1490.52% in 2022.
• Over 5 years, Free Cash Flow stood at -$3.2 million in 2021, then surged by 44.22% to -$1.8 million in 2022, then advanced by 21.47% to -$1.4 million in 2023, then retreated by 7.87% to -$1.5 million in 2024, then slumped by 38.41% to -$2.1 million in 2025.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$2.1 million, -$1.7 million, and -$1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.